GARDEN CITY, N.Y.--(BUSINESS WIRE)--ImaCor Inc., the developer of the world’s only hemodynamic transesophageal echocardiography (hTEE™) management device, announced that the first in a planned series of symposia presenting hTEE study findings and cases was held October 14th in Lisbon, Portugal. Coinciding with the 25th Annual European Society of Intensive Care Medicine (ESICM) LIVES Congress, the evening showcased an unparalleled group of eleven global critical care leaders sharing their clinical work using hTEE to better manage ICU patients.
The 3-hour symposium spotlighted clinical results, including findings of a multi-center hTEE study, as well as impactful trauma, cardiac and general ICU hTEE cases. Cases evidenced hTEE as providing vital information for changing patient management, including evaluation of left and right ventricular function, assessment of volume status, and early identification of cardiac tamponade. Presenters underscored the value of the episodic, hemodynamic monitoring made possible through the miniaturized, disposable hTEE ClariTEE® probe, which can be left in the patient for up to 72-hours.
The hTEE symposium presenters were:
- Jan Bakker MD, PhD of Erasmus MC (NL)
- Maurizio Cecconi MD of St. George’s University Hospital (UK)
- Daniel De Backer MD, PhD, the ESICM President-Elect, of Hōpital Erasme (BE)
- Nick Fletcher MD of St. George’s University Hospital (UK)
- Tobias Merz MD of Bern Inselspital (SZ)
- Rui Moreno MD, PhD of Hospital São José (PT)
- Michael Pinsky MD of University of Pittsburgh Medical Center (US)
- Jan Poelaert MD, PhD of UZ Brussels (BE)
- Michel Slama MD, PhD of CHU Amiens (FR)
- Antoine Vieillard-Baron MD, PhD of CHU Ambroise Paré (FR)
- Philippe Vignon MD, PhD of CHU Dupuytren (FR)
“Hemodynamic instability is a critical condition that often leads to severe patient complications,” said Scott L. Roth MD, FACC, the Co-Founder/CMO of ImaCor. “The hTEE studies and cases shared by this distinguished coalition of physicians support better management of ICU patients through hTEE technology.”
“This event heralds an advanced stage in ImaCor’s development, one exemplifying our long-term commitment to sharing hTEE clinical efficacy and ICU cost containment solutions,” commented Peter Pellerito, the President/CEO of ImaCor.
Additional hTEE symposia focused on cardiac and trauma critical care are scheduled throughout 2013.
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare resources. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™, and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacorinc.com.